<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485729</url>
  </required_header>
  <id_info>
    <org_study_id>ONC012</org_study_id>
    <nct_id>NCT03485729</nct_id>
  </id_info>
  <brief_title>ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer</brief_title>
  <official_title>A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in&#xD;
      women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior&#xD;
      chemotherapy regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>2 months</time_frame>
    <description>PFS2</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endometrial Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Biopsy-mandated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Biopsy-optional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing twice per week on two consecutive days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONC201</intervention_name>
    <description>ONC201</description>
    <arm_group_label>Biopsy-mandated</arm_group_label>
    <arm_group_label>Biopsy-optional</arm_group_label>
    <arm_group_label>Dosing twice per week on two consecutive days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic or recurrent Type II EC (serous, clear cell,&#xD;
             carcinosarcoma, adenosquamous and mixed histologies).&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension in accordance with RECIST criteria&#xD;
             v.1.1.&#xD;
&#xD;
          -  Availability of at least 12 unstained slides from archival FFPE tumor tissue.&#xD;
&#xD;
          -  For Arm A, patients must have disease that is amenable to biopsy and must be willing&#xD;
             to provide consent for a tumor biopsy at baseline (within 30 days of beginning ONC201)&#xD;
             and at least 1 on-treatment tumor biopsy.&#xD;
&#xD;
          -  Must have radiographic disease progression after at least 1 line of systemic cytotoxic&#xD;
             therapy for metastatic disease or with progression within 12 months of completing&#xD;
             adjuvant chemotherapy.&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  Patients must have adequate bone marrow, hepatic and renal function as defined below:&#xD;
&#xD;
               -  Leukocytes &gt; 3,000/mcL&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,500/mcL&#xD;
&#xD;
               -  Platelets &gt; 100,000/mcL&#xD;
&#xD;
               -  Total bilirubin ≤1.5 ULN&#xD;
&#xD;
               -  AST/ALT (SGOT/SGPT) &lt; 2 ULN&#xD;
&#xD;
               -  Creatinine ≤1.5 ULN OR&#xD;
&#xD;
               -  Creatinine clearance &gt; 60 Ml/min/1.73 m2 for patients with creatinine levels&#xD;
                  above ULN calculated using Calvert formula&#xD;
&#xD;
          -  Life expectancy at least 3 months.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent and HIPAA&#xD;
             consent document.&#xD;
&#xD;
          -  Patients must be surgically sterile or be postmenopausal, or must agree to use&#xD;
             effective contraception during the period of the trial and for at least 90 days after&#xD;
             completion of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior treatment with ONC201.&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering&#xD;
             the study or those who have not recovered from adverse events due to agents&#xD;
             administered more than 4 weeks earlier.&#xD;
&#xD;
          -  The subjects who have not recovered to baseline or CTCAE ≤ Grade 1 from related&#xD;
             toxicity to all prior therapies will be excluded. Patients with Non-serious adverse&#xD;
             events such as alopecia, fatigue, weakness, loss of appetite and nausea that are&#xD;
             non-significant will not be excluded.&#xD;
&#xD;
          -  Any other prior malignancy from which the patient has been disease free for less than&#xD;
             3 years, with the exception of adequately treated and cured basal or squamous cell&#xD;
             skin cancer, superficial bladder cancer, carcinoma in situ of any site.&#xD;
&#xD;
          -  The subject is unable to swallow capsules.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of ONC201 (uncontrolled nausea, vomiting, diarrhea, malabsorption&#xD;
             syndrome, or small bowel resection).&#xD;
&#xD;
          -  Patients receiving any other investigational agents.&#xD;
&#xD;
          -  Patients with symptomatic brain metastases are excluded. Patients with asymptomatic&#xD;
             and treated CNS metastases may participate in this trial. The patient must have&#xD;
             completed any prior treatment for CNS metastases &gt; 28 days prior to study entry&#xD;
             including radiotherapy or surgery. Steroids for the treatment of brain metastasis are&#xD;
             not permitted, and patients must be stable off steroid treatment for 4 weeks prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection. Any of the following in the previous 6 months: myocardial infarction,&#xD;
             severe/unstable angina, coronary/peripheral artery bypass graft, cerebrovascular&#xD;
             accident, transient ischemic attack or symptomatic pulmonary embolism.&#xD;
&#xD;
          -  Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to&#xD;
             underlying malignancy or prior related treatment) or history of abdominal fistula,&#xD;
             gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within&#xD;
             6 months prior to study enrollment. Gastroesophageal reflux disease under treatment&#xD;
             with proton pump inhibitors is allowed.&#xD;
&#xD;
          -  Known HIV-positive patients on combination antiretroviral therapy.&#xD;
&#xD;
          -  Known history of HBV or HCV infection.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, or may interfere with the interpretation of study results, or in&#xD;
             the judgment of the investigator would make the patient inappropriate for entry into&#xD;
             the study.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samuel Ramage, PhD</last_name>
    <phone>919-806-1074</phone>
    <email>sramage@chimerix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tabatha Rodebaugh</last_name>
    <email>TRodebaugh@chimerix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rutgers, The State University of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorna Rodriguez, MD PhD</last_name>
      <phone>732-235-2465</phone>
      <email>rodriglo@cinj.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Gruhn, MS</last_name>
      <phone>919-445-4212</phone>
      <email>jennifer_gruhn@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Victoria L Bae-Jump, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Mantia-Smaldone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gina Mantia-Smaldone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 25, 2018</study_first_submitted>
  <study_first_submitted_qc>March 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TIC10 compound</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

